This is an old revision of this page, as edited by PotatoBot (talk | contribs) at 18:15, 10 September 2011 (Stub sorting and placement of stub template(s): antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 18:15, 10 September 2011 by PotatoBot (talk | contribs) (Stub sorting and placement of stub template(s): antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 12 to 35 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.196.628  |
| Chemical and physical data | |
| Formula | C25H27FN4O3 |
| Molar mass | 450.505 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
| (verify) | |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.
It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
On 8th March 2010, AstraZeneca issued a press-release stating that Recentin had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader Avastin.
References
- Wedge SR, Kendrew J, Hennequin LF; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Goss G, Shepherd FA, Laurie S; et al. (2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer. 45 (5): 782. doi:10.1016/j.ejca.2008.10.022. PMID 19091548.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Nikolinakos P, Heymach JV (2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol. 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296.
{{cite journal}}: Unknown parameter|month=ignored (help)
http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245
External links
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |